Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation
Version of Record online: 11 FEB 2011
© 2011 The Authors. Sociology of Health & Illness © 2011 Foundation for the Sociology of Health & Illness/Blackwell Publishing Ltd
Sociology of Health & Illness
Volume 33, Issue 5, pages 731–747, July 2011
How to Cite
Davis, C. and Abraham, J. (2011), Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociology of Health & Illness, 33: 731–747. doi: 10.1111/j.1467-9566.2010.01310.x
- Issue online: 20 JUL 2011
- Version of Record online: 11 FEB 2011
- 1994) Bias in science and medical knowledge, Sociology, 28, 717–36. (
- 1995) Science, Politics and the Pharmaceutical Industry. London/New York: UCL/St. Martins Press. (
- 2008) Sociology of pharmaceuticals development and regulation: a realist empirical research programme, Sociology of Health and Illness, 30, 869–85. (
- 2009) Partial progress: governing the pharmaceutical industry and NHS, 1948–2008, Journal of Health, Politics, Policy and Law, 34, 931–77. (
- 2010) Pharmaceuticalization of society in context, Sociology, 44, 603–22. (
- 2005a) Risking public safety, Health, Risk and Society, 7, 379–95. and (
- 2005b) Comparative analysis of drug safety withdrawals in UK and US, 1971–1992, Social Science and Medicine, 61, 881–92. and (
- 2006) Testing times: the emergence of the Practolol disaster and its challenge to British drug regulation, Social History of Medicine, 19, 127–47. and (
- 2007) Deficits, expectations and paradigms in British and American drug safety assessments, Science, Technology & Human Values, 32, 399–431. and (
- 2009) Drug evaluation and the permissive principle: continuities and contradictions in antidepressant regulation, Social Studies of Science, 39, 569–98. and (
- 1999) Harmonising and competing for medicines regulation: how healthy are the EU’s systems of drug approval? Social Science and Medicine, 48, 1655–67. and (
- 2000) Regulating Medicines in Europe. London: Routledge. and (
- 2002) Citizenship, medical expertise, and the capitalist regulatory state in Europe, Sociology, 36, 67–88. and (
- 1999) The Therapeutic Nightmare: The Battle over the World’s most Controversial Sleeping Pill. London: Earthscan. and (
- 1997) Working from the inside out: implications of breast cancer activism for biomedical policies and practices, Social Science and Medicine, 44, 1403–1415. (
- Anon. (1981a) Change of attitude at FDA called ‘essential’ by Reagan advisor, Scrip, 558, 12.
- Anon. (1981b) US ‘drug lag’ Commission starts work, Scrip, 611, 10.
- Anon. (1981c) Pressure affects BuDrugs morale, Scrip, 642, 7.
- Anon. (1982a) US NDA rewrite published, Scrip, 739, 8.
- Anon. (1982b) Deregulation hurts FDA morale, Scrip, 685, 10.
- Anon. (1985) FDA’s willingness to help, Scrip, 993, 17.
- Anon. (1986a) Dr Young outlines Action Plan progress, Scrip, 1074, 16.
- Anon. (1986b) PMA/FDA co-operation, Scrip, 1096, 19.
- Anon. (1987) ‘US PMA meeting’s hidden concerns’, Scrip, 1213, 19.
- Anon. (1988a) FDA discussing new proposals, Scrip, 1336, 16.
- Anon. (1988b) Bush calls for speedier US approvals, Scrip, 1335, 16.
- Anon. (1988c) FDA’s expedited drug plan unveiled, Scrip, 1356, 18.
- Anon. (1988d) US PMA comments on expedited drug plan, Scrip, 1346, 17.
- Anon. (1989a) FDA battles NIAID on AIDS, Scrip, 1450, 19.
- Anon. (1989b) FDA and drug approval, Scrip, 1378, 17.
- Anon. (1989c) NCI/FDA clash on cancer approvals, Scrip, 1382, 16.
- Anon. (1990a) Mixed review for AIDS/cancer panel report, Scrip, 1546, 18.
- Anon. (1990b) AIDS activists urge ddI/ddC approval, Scrip, 1557, 30.
- Anon. (1991a) FDA discusses conditional approvals, Scrip, 1598, 17.
- Anon. (1991b) PMA on conditional approvals, Scrip, 1624, 18.
- Anon. (1994) Change afoot for FDA, Scrip, 1983, 18.
- Anon. (1995a) BIO’s proposals for FDA reform, Scrip, 2006, 17.
- Anon. (1995b) PhRMA’s FDA reform plan, Scrip, 2040, 16.
- Anon. (1995c) FDA bill reflects industry views, Scrip, 2043, 14.
- Anon. (1997) Senate approves FDA reform bill, Scrip, 2272, 15.
- Anon. (2002) More Iressa ADRs in Japan, Scrip, 2794, 23.
- Anon. (2009) Iressa set to make it as second asking, Cancer Drug News, 30 April, 1–2.
- 2005) Ten years of marketing approvals of anticancer drugs in Europe, British Journal of Cancer, 93, 504–9. , , and (
- 2002) Demand grows for early access to promising cancer drugs, Journal of National Cancer Institute, 94, 1668–70. (
- 2004) New Medical Technologies and Society. Cambridge: Polity. and (
- 2004) Mental health problems, psychotropic drug technologies and risk, Health, Risk and Society, 6, 361–75. (
- 2004) Political economy of FDA, Health Affairs, 23, 52–63. (
- 1996) Reinventing the Regulation of Cancer Drugs. Washington DC: National Performance Review. and (
- 2002) ‘Briefing document,NDA-21399’ FDA Oncology Division Medical Review. Rockville, Maryland: FDA. US FOIA request. (
- 2007) Medicalization of society. Baltimore, MD: Johns Hopkins University Press. (
- 2004) Pharmacopolitics. Chapel Hill, NC: University of North Carolina Press. (
- 2000) Risk versus risk, Science as Culture, 9, 505–34. and (
- 1990) The challenge of AIDS to the regulatory process, Milbank Quarterly, 68, 111–42. and (
- 1996) Impure Science: AIDS Activism, and the Politics of Knowledge. Berkeley, CA: University of California Press. (
- 1997) Activism, drug regulation and the politics of therapeutic evaluation in the AIDS era, Social Studies of Science, 27, 691–726. (
- European Commission (EC) (1993) Article 13(2), Regulation 2309/93. Brussels: EC.
- FDA (1998a) Guidance for Industry: Fast-track Drug Development Programs. Rockville, MD: HHS.
- FDA (1998b) Guidance for Industry: Approval of New Cancer Treatment Uses. Rockville, MD: HHS.
- FDA (2002) Transcript, Oncological Drugs Advisory Committee (ODAC) Meeting, 24 September. Silver Spring, MD.
- FDA (2003) Approval Package, Iressa, 1 April. Rockville: HHS.
- FDA (2005) Transcript, ODAC Meeting, 4 March. Gaithersburg, MD.
- Federal Register (FR) (1985) New drug and antibiotic regulations, 50, FR, 7452. Washington DC: GPO.
- Federal Register (FR) (1987) New drug, antibiotic and biologic drug product regulations, 52, FR, 8798. Washington DC: GPO.
- Federal Register (FR) (1988) Procedures for drugs intended to treat life-threatening and severely debilitating illnesses, 53, FR, 41516. Washington DC: GPO.
- Federal Register (FR) (1992) Accelerated approval, 57, FR, 58958. Washington DC: GPO.
- 1998) Resurgent regulation in the US. In Doern, G.B. and Wilks, S. (eds) Changing Regulatory Institutions in Britain and North America. Toronto: University of Toronto Press. (
- 2005) Surrogate endpoints and FDA’s accelerated approval process, Health Affairs, 24, 67–78. (
- 2009) Living drugs, Science as Culture, 18, 123–31. , and (
- 1988) Tranquillisers as a social problem, Sociological Review, 36, 320–52. and (
- 1996) Halcyon nights: a sociological account of medical controversy, Sociology, 30, 447–69. and (
- 2001) Adjusting Europe’s drug regulation to public health needs, Lancet, 358, 66. and (
- 2005) An ‘insurgency’ targets randomized trials, The Cancer Letter, 31, 10–15. (
- 2003) Protecting America’s Health. New York: Knopf. (
- 1985) FDA requirements for approval of anti-cancer drugs, Cancer Treatment Reports, 69, 1155–59. and (
- 2003) Endpoints and FDA approval of oncology drugs, Journal of Clinical Oncology, 21, 1404–11. , and (
- 1996) Medicalization and pharmacological treatment of blood pressure. In Davis, P. (ed) Contested Ground. Oxford: Oxford University Press. and (
- National Academy of Sciences (NAS) (1983) Competitive Status of the US Pharmaceutical Industry. Washington DC: National Academy Press.
- 1994) The Politics of US Health Policy. Oxford: Blackwell. (
- Office of Technology Assessment (OTA) (1993) Costs, Risks and Rewards, Washington DC: GPO.
- Official Journal of the European Union (OJEU) (2004) OJL13630.4.2004 of European Parliament and Council, Community procedures for authorisation and supervision of medicinal products, paragraph 33. Brussels: EU.
- Patients’ Coalition (1996) Issues of Concern to Patients in Debate over FDA Reform, 20 March. Washington, DC: Patients Coalition.
- Patients’ Coalition (1997) Testimony, Jeff Bloom, Patients Coalition, Commerce Committee and Health and Environment SubCommittee, House of Representatives, 12 April. Washington, DC: Patients Coalition.
- 1996) Adverse reactions, social responses: two asthma mortality epidemics. In Davis, P. (ed) Contested Ground. Oxford: Oxford University Press. (
- 2005) Exploring clinician uncertainty in diagnosis and treatment of ADHD, Sociology of Health and Illness, 27, 305–23. (
- 2004) Beyond fast-track for drug approvals, New England Journal of Medicine, 351, 502. and (
- 2006) Change in the policy community of human genetics, Policy and Politics, 34, 347–66. and (
- 2001) The Transnational Capitalist Class. Oxford: Blackwell. (
- 2003) Lessons from ‘Iressa’: expanded access programme, British Journal of Cancer, 89, 19–23. , , , et al. (
- US Government Accountability Office (US GAO) (2009) New Drug Approval: Report to Committee on Finance, US Senate. GAO-09-866: GPO. Washington, DC: GAO.
- 2002) Team Leader Comments (Iressa), FDA Oncology Drugs Division, 24 September. Rockville, Maryland: FDA. US FOIA request. (
- Williams, S.J., Gabe, J. and Davis, P. (eds) (2009) Pharmaceuticals and Society. Chichester: Wiley-Blackwell.
- 2008) Modafinil, the media and pharmaceuticalisation of everyday/night life, Sociology of Health and Illness, 30, 839–55. , , , and (
- 2000) How a new policy led to seven deadly drugs, Los Angeles Times, 20 December, 6. (